Please select the option that best describes you:

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?   

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this change if ECOG 2?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Winthrop Hospital
Great discussion
Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
LAURA ‘overwhelmingly’ positive for PF...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
In regards to the LAURA trial -  Consolidati...
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
I have news for you. The Osi arm gets indefinite t...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
Interesting approach. Then, I would hope and expe...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more